Dose optimisation of PTEN inhibitor, bpV (HOpic), and SCF for the in-vitro activation of sheep primordial follicles.
Animals
Cells, Cultured
Female
Ovarian Follicle
/ growth & development
PTEN Phosphohydrolase
/ antagonists & inhibitors
Phosphatidylinositol 3-Kinase
/ biosynthesis
Sheep
Signal Transduction
/ drug effects
Stem Cell Factor
/ pharmacology
Tumor Suppressor Protein p53
/ antagonists & inhibitors
Vanadium Compounds
/ pharmacology
Follicular activation
PTEN inhibitor
primordial follicle
stem cell factor
Journal
Growth factors (Chur, Switzerland)
ISSN: 1029-2292
Titre abrégé: Growth Factors
Pays: England
ID NLM: 9000468
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
28
10
2019
medline:
16
4
2020
entrez:
25
10
2019
Statut:
ppublish
Résumé
The in-vitro development of primordial follicles is critical for improving mammalian fertility and wildlife conservation. This study aimed to optimise the effective doses of bpV (HOpic) and stem cell factor (SCF) for the in-vitro activation of sheep primordial follicles. To do this, sheep ovarian cortex was treated with bpV (1.5, 15, and 150 μM) and SCF (50 and 100 ng/ml). Follicular count indicated that 15 μM bpV and 100 ng/ml SCF significantly increased normal primary follicles compared to other groups (
Identifiants
pubmed: 31646909
doi: 10.1080/08977194.2019.1680661
doi:
Substances chimiques
Stem Cell Factor
0
Tumor Suppressor Protein p53
0
Vanadium Compounds
0
bisperoxovanadium
0
Phosphatidylinositol 3-Kinase
EC 2.7.1.137
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM